Fabbro Elisa, Lamichhane Usha, Sudbrak Ralf, Ogilvie Lesley, Vitiello Antonio, Zovi Andrea, Sabbatucci Michela
Area Science Park, Padriciano 99, 34149, Trieste, Italy.
Global AMR R&D Hub, Schlüterstrasse 39, 10629, Berlin, Germany.
Eur J Health Econ. 2025 May 26. doi: 10.1007/s10198-025-01796-1.
Antimicrobial resistance (AMR) remains one of the world's most pressing health, economic, and social challenges. To combat this crisis, innovative tools have been developed to enhance research and development (R&D) efforts like the Global AMR R&D Hub's Dynamic Dashboard. By aggregating data from projects worldwide, the Dynamic Dashboard highlights trends and gaps in AMR R&D investments, totalling more than 8.22 billion Euros in the period 2017-2021 across the One Health continuum - human, animal, plant and environment. Launched in March 2020, the Dynamic Dashboard supports global priority setting and decision-making in AMR research, fostering strategic planning to promote efficient use of international resources and cross sectoral collaboration in AMR R&D.
Recognizing the urgent need for innovative diagnostics, treatments, and prevention strategies against AMR, here we presented a comprehensive analysis of public and philanthropic investments in AMR R&D obtained from January 2017 to December 2021 across Europe.
We calculated the investments by One Health sector, year of funding, gross domestic product (GDP), research area, type of project, and infectious agent to raise awareness and promote global visibility of the R&D landscape in Europe. Our analysis revealed limited AMR R&D investments in the non-human sectors and non-bacterial topics, geographical polarization of funders, and some unaligned trends between the amount of investments and number of projects funded over the study period.
Harnessing these data-driven insights, we aimed to inform stakeholders and optimize the allocation of economic resources for AMR R&D. Prioritizing unmet needs with the greatest potential for impact in this field will expedite the development of effective solutions to mitigate the global threat of AMR.
抗菌药物耐药性（AMR）仍然是全球最紧迫的健康、经济和社会挑战之一。为应对这一危机，已开发出创新工具来加强研发工作，如全球抗菌药物耐药性研发中心的动态仪表板。通过汇总来自全球项目的数据，动态仪表板突出了抗菌药物耐药性研发投资的趋势和差距，在2017年至2021年期间，“同一个健康”连续体（人类、动物、植物和环境）中的投资总额超过82.2亿欧元。动态仪表板于2020年3月推出，支持抗菌药物耐药性研究中的全球优先事项设定和决策，促进战略规划，以推动国际资源的有效利用以及抗菌药物耐药性研发中的跨部门合作。
认识到对抗菌药物耐药性的创新诊断、治疗和预防策略的迫切需求，我们在此对2017年1月至2021年12月期间欧洲公共和慈善机构在抗菌药物耐药性研发方面的投资进行了全面分析。
我们按“同一个健康”部门、资助年份、国内生产总值（GDP）、研究领域、项目类型和感染因子计算了投资，以提高对欧洲研发格局的认识并提升其全球知名度。我们的分析揭示了非人类部门和非细菌主题的抗菌药物耐药性研发投资有限、资助者的地域两极分化，以及在研究期间投资金额与资助项目数量之间的一些不一致趋势。
利用这些数据驱动的见解，我们旨在为利益相关者提供信息，并优化抗菌药物耐药性研发的经济资源分配。优先考虑该领域中具有最大潜在影响的未满足需求，将加快有效解决方案的开发，以减轻抗菌药物耐药性的全球威胁。
